Evolus Inc (EOLS)
NASDAQ:EOLS

Evolus (EOLS) Stock Price & Analysis

330 Followers

EOLS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$6.51 - $14.34
Previous Close$10.5
Volume458.91K
Average Volume (3M)436.00K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$65.57M
Total Debt (Recent Filing)$74.51M
Price to Earnings (P/E)-7.4
Beta0.34
Next EarningsMar 01, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.42
Shares Outstanding56,246,570
R-Squared0.05
Standard Deviation0.43
10 Day Avg. Volume524,176
30 Day Avg. Volume436,005
Price to Book (P/B)-14.40
Price to Sales (P/S)5.92
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-7.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside63.55% Upside
Rating ConsensusStrong Buy
Alpha0.03
Number of Analyst Covering5


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

EOLS FAQ

What was Evolus’s price range in the past 12 months?
Evolus lowest stock price was $6.51 and its highest was $14.34 in the past 12 months.
    What is Evolus’s market cap?
    Currently, no data Available
    When is Evolus’s upcoming earnings report date?
    Evolus’s upcoming earnings report date is Mar 01, 2023 which is in 33 days.
      How were Evolus’s earnings last quarter?
      Evolus released its earnings results on Nov 08, 2022. The company reported -$0.278 earnings per share for the quarter, beating the consensus estimate of -$0.308 by $0.03.
        Is Evolus overvalued?
        According to Wall Street analysts Evolus’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Evolus pay dividends?
          Evolus does not currently pay dividends.
          What is Evolus’s EPS estimate?
          Evolus’s EPS estimate is -$0.18.
            How many shares outstanding does Evolus have?
            Evolus has 56,246,570 shares outstanding.
              What happened to Evolus’s price movement after its last earnings report?
              Evolus reported an EPS of -$0.278 in its last earnings report, beating expectations of -$0.308. Following the earnings report the stock price went down -9.126%.
                Which hedge fund is a major shareholder of Evolus?
                Among the largest hedge funds holding Evolus’s share is Deerfield Management Company, LP. It holds Evolus’s shares valued at 43M.

                  ---

                  Evolus Stock Smart Score

                  The Evolus stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Evolus Inc

                  Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Bakhu Holdings
                  NGM Biopharmaceuticals
                  Tarsus Pharmaceuticals
                  Rani Therapeutics Holdings

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis